<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04731558</url>
  </required_header>
  <id_info>
    <org_study_id>HYKS-PREPOSTEROUS</org_study_id>
    <nct_id>NCT04731558</nct_id>
  </id_info>
  <brief_title>Pre- vs Postoperative Thromboprophylaxis for Liver Resection</brief_title>
  <acronym>PREPOSTEROUS</acronym>
  <official_title>Pre- vs Postoperative Thromboprophylaxis for Liver Resection - a Prospective, Multicenter, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Academy of Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Finnish Medical Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Thromboprophylaxis for liver surgery can be commenced either preoperatively or&#xD;
      postoperatively. Despite a clear trade-off between thrombosis and bleeding in liver surgery&#xD;
      patients, there is no international consensus when thrombosis prophylaxis should be commenced&#xD;
      in patients undergoing liver surgery. As far as we know, there are no prospective randomized&#xD;
      trials in this field, and current guidelines are unfortunately based on very low quality&#xD;
      evidence, that is, a few retrospective studies and expert opinion. Both American and European&#xD;
      thromboprophylaxis guidelines for abdominal cancer surgery support the preoperative&#xD;
      initiation of thromboprophylaxis, but these guidelines do not specifically address the&#xD;
      increased bleeding risk associated with liver surgery. On the contrary, Dutch guidelines&#xD;
      recommend postoperative thromboprophylaxis only, because of lack of evidence for preoperative&#xD;
      thromboprophylaxis. Traditionally, many liver surgery units have been reluctant in using&#xD;
      preoperative thromboprophylaxis due to the potentially increased risk of bleeding&#xD;
      complications. Enhanced Recovery After Surgery (ERAS) Society Guidelines recommend&#xD;
      preoperative thromboprophylaxis in liver surgery, but the guidelines provide no supporting&#xD;
      evidence for this recommendation. Overall, the amount of evidence is scarce and somewhat&#xD;
      contradictory in this clinically relevant field of thromboprophylaxis in liver surgery. The&#xD;
      aim of this study is to compare pre- and postoperatively initiated thromboprophylaxis&#xD;
      regimens in liver surgery in a randomized controlled trial.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 10, 2021</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">February 2025</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Venous thromboembolisms</measure>
    <time_frame>within 30 days from liver resection</time_frame>
    <description>Number of patients with venous thromboembolism defined as either 1) symptomatic deep venous thromboembolism (includes all deep veins e.g. all extremities, portal vein, and superior mesenteric) diagnosed using ultrasound or computed tomography or magnetic resonance imaging, or in re-laparatomy/surgery, 2) pulmonary embolism diagnosed using computed tomography, magnetic resonance imaging, or lung perfusion imaging, or 3) death due to venous thromboembolism</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Posthepatectomy haemorrhage</measure>
    <time_frame>within 30 days from liver resection</time_frame>
    <description>Number of patients with posthepatectomy haemorrhage, any grade in ISGLS classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complications</measure>
    <time_frame>within 30 days from liver resection</time_frame>
    <description>Comprehensive Complication Index - score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of postoperative hospital stay</measure>
    <time_frame>within 30 days from liver resection</time_frame>
    <description>Length of postoperative hospital stay, days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood transfusion</measure>
    <time_frame>during and within 30 days from liver resection</time_frame>
    <description>Total amount of transfused red blood cells, units</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1012</enrollment>
  <condition>Liver Cancer</condition>
  <condition>Surgery</condition>
  <condition>Thrombosis, Deep Vein</condition>
  <condition>Embolism, Pulmonary</condition>
  <condition>Bleeding</condition>
  <arm_group>
    <arm_group_label>Preoperative thromboprophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preoperatively initiated tromboprophylaxis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Postoperative thromboprophylaxis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Postoperatively initiated thromboprophylaxis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>enoxaparin or tinzaparin or dalteparin</intervention_name>
    <description>Thromboprophylaxis initiated approximately 14 hours prior to the planned liver resection skin incision. Thromboprophylaxis can be initiated using enoxaparin (20 - 40 mg), tinzaparin (2500 - 4500 IU), or dalteparin (2500 - 5000 IU), with the dose based on patient's renal function</description>
    <arm_group_label>Preoperative thromboprophylaxis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No preoperative thromboprophylaxis.</description>
    <arm_group_label>Postoperative thromboprophylaxis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients undergoing liver resection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient on anticoagulative medication (heparin, low-molecular weight heparin,&#xD;
             warfarin, direct oral anticoagulants) during last month pre-surgery&#xD;
&#xD;
          -  Emergency operation (e.g. for trauma or infection)&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  Allergy or other contraindication to planned low-molecular weight heparin&#xD;
&#xD;
          -  Inability to give written informed consent&#xD;
&#xD;
          -  Liver resection not performed (removed from analyses after randomization)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ville Sallinen, MD, PhD</last_name>
    <phone>+358-9-4711</phone>
    <email>ville.sallinen@helsinki.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aki Uutela, MD</last_name>
      <phone>+358-9-4711</phone>
      <email>aki.uutela@hus.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kuopio University Hospital</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pekka Lammi, MD</last_name>
      <email>pekka.lammi@kys.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oulu University Hospital</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Heikki Karjula, MD, PhD</last_name>
      <email>heikki.karjula@ppshp.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yrj√∂ Vaalavuo, MD</last_name>
      <email>yrjo.vaalavuo@pshp.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maija Lavonius, MD</last_name>
      <email>maija.lavonius@tyks.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sheraz Yaqib, MD</last_name>
      <email>shya@ous-hf.no</email>
    </contact>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Norway</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 26, 2021</study_first_submitted>
  <study_first_submitted_qc>January 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2021</study_first_posted>
  <last_update_submitted>May 31, 2021</last_update_submitted>
  <last_update_submitted_qc>May 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Ville Sallinen</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enoxaparin</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Tinzaparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

